Xenon Pharmaceuticals Inc. (XENE)
USD 39.35
(-4.68%)
USD 39.35
(-4.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -145.32 Million | -98.43 Million | -69.5 Million | -48.12 Million | -4.63 Million | -34.72 Million |
| Net Income | -182.39 Million | -125.37 Million | -78.88 Million | -28.83 Million | -41.59 Million | -34.49 Million |
| Depreciation & Amortization | 3.54 Million | 1.62 Million | 906 Thousand | 644 Thousand | 429 Thousand | 586 Thousand |
| Deferred income taxes | -292 Thousand | -44 Thousand | 58 Thousand | -285 Thousand | -133 Thousand | 646 Thousand |
| Stock-based compensation | 32.37 Thousand | 20.37 Million | 10.01 Million | 5.67 Million | 2.92 Million | 2.62 Million |
| Change in working capital | 5.63 Million | -676 Thousand | -2.64 Million | -26.08 Million | 33.52 Million | 30 Thousand |
| Other non-cash items | -4.19 Million | 5.66 Million | 1.04 Million | 766 Thousand | 223 Thousand | -4.11 Million |
| Investing Cash Flow | -117.17 Million | -296 Million | -246.77 Million | -16.82 Million | -66.29 Million | -28.98 Million |
| Investments in PPE | -5.61 Million | -2.89 Million | -2.05 Million | -2.63 Million | -1.24 Million | -507 Thousand |
| Acquisitions | -682.35 Million | 296 Million | -144.75 Million | -214.71 Million | -75.44 Million | -48.52 Million |
| Investment purchases | -793.9 Million | -551.13 Million | -389.47 Million | -228.89 Million | -140.49 Million | -77 Million |
| Sales/Maturities of investments | 682.35 Million | 258.02 Million | 144.75 Million | 214.71 Million | 75.44 Million | 48.52 Million |
| Other Investing Activities | 682.35 Million | -296 Million | 144.75 Million | 214.71 Million | 75.44 Million | 48.52 Million |
| Financing Cash Flow | 353.52 Million | 278.47 Million | 447.54 Million | 85.79 Million | 27.51 Million | 111.59 Million |
| Debt repayment | - | - | - | -16.74 Million | - | -8.45 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 353.52 Million | 278.47 Million | 447.28 Million | 102.45 Million | 27.39 Million | 102.85 Million |
| Other Financing Activities | 353.52 Million | 278.47 Million | 260 Thousand | 82 Thousand | 122 Thousand | 8.74 Million |
| Accounts receivables | 130 Thousand | 1.75 Million | -459 Thousand | -1.03 Million | -653 Thousand | 175 Thousand |
| Accounts payables | 3.93 Million | 8.06 Million | 2.97 Million | 2.02 Million | 4.54 Million | 783 Thousand |
| Inventory | - | - | -2.97 Million | -2.02 Million | -4.54 Million | -783 Thousand |
| Other working capital | 1.57 Million | -10.49 Million | -2.18 Million | -25.05 Million | 34.17 Million | -145 Thousand |
| Cash at beginning of period | 57.24 Million | 175.68 Million | 45 Million | 24.75 Million | 67.75 Million | 20.48 Million |
| Cash at end of period | 148.64 Million | 57.24 Million | 175.68 Million | 45 Million | 24.75 Million | 67.75 Million |
| Capital Expenditure | -5.61 Million | -2.89 Million | -2.05 Million | -2.63 Million | -1.24 Million | -507 Thousand |
| Effect of forex changes on cash | 376 Thousand | -2.48 Million | -592 Thousand | -593 Thousand | 406 Thousand | -612 Thousand |
| Net cash flow / Change in cash | 91.4 Million | -118.44 Million | 130.67 Million | 20.25 Million | -42.99 Million | 47.26 Million |
| Free Cash Flow | -150.94 Million | -101.32 Million | -71.55 Million | -50.76 Million | -5.87 Million | -35.23 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -57.92 Million | -47.93 Million | -182.39 Million | -44.74 Million | -48.46 Million | -47.46 Million |
| Depreciation & Amortization | 659 Thousand | 599 Thousand | 3.54 Million | 851 Thousand | 1.73 Million | 602 Thousand |
| Deferred income taxes | -333.49 Thousand | 403 Thousand | -292 Thousand | -196.97 Thousand | -156 Thousand | -224 Thousand |
| Stock-based compensation | 14.71 Million | 9.4 Million | 32.37 Million | 9.18 Million | 8.74 Million | 8.45 Million |
| Change in working capital | 10.05 Million | -5.65 Million | 5.63 Million | -598.88 Thousand | -3.29 Million | 6.89 Million |
| Other non-cash items | 7.61 Million | 15.58 Million | -4.19 Million | 1.81 Million | -791 Thousand | -1.48 Million |
| Investing Cash Flow | 110.26 Million | -46.2 Million | -117.17 Million | -239.18 Million | 48.03 Million | 27.9 Million |
| Investments in PPE | -1.5 Million | -188 Thousand | -5.61 Million | -3875.51 | -1.2 Million | -2.13 Million |
| Acquisitions | - | - | -682.35 Million | 236.37 Million | -49.23 Million | -30.03 Million |
| Investment purchases | -122.84 Million | -176.84 Million | -793.9 Million | -367.64 Million | -146.76 Million | -162.27 Million |
| Sales/Maturities of investments | 234.6 Million | 130.83 Million | 682.35 Million | 128.47 Million | 195.99 Million | 192.3 Million |
| Other Investing Activities | 112.23 Million | 130.83 Million | 682.35 Million | -236.37 Million | 49.23 Million | 30.03 Million |
| Financing Cash Flow | - | - | 353.52 Million | 320.69 Million | 29.5 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 353.52 Million | 320.69 Million | 29.5 Million | - |
| Other Financing Activities | - | - | 353.52 Million | 353.52 Million | 29.5 Million | - |
| Accounts receivables | -22.11 Thousand | 38 Thousand | 130 Thousand | -296.95 Thousand | 155 Thousand | 43 Thousand |
| Accounts payables | 9.12 Million | -5.01 Million | 3.93 Million | 2.25 Million | -3.36 Million | 5.59 Million |
| Inventory | - | - | - | 2.23 Million | 3.36 Million | -5.59 Million |
| Other working capital | 955.98 Thousand | -673 Thousand | 1.57 Million | -4.79 Million | -3.45 Million | 6.84 Million |
| Cash at beginning of period | 58.89 Million | 148.64 Million | 57.24 Million | 99.57 Million | 64.55 Million | 69.51 Million |
| Cash at end of period | 136.73 Million | 58.89 Million | 148.64 Million | 148.64 Million | 99.57 Million | 64.55 Million |
| Capital Expenditure | -1.5 Million | -188 Thousand | -5.61 Million | -3875.51 | -1.2 Million | -2.13 Million |
| Effect of forex changes on cash | -202 Thousand | -367 Thousand | 376 Thousand | 246 Thousand | -288 Thousand | 359 Thousand |
| Net cash flow / Change in cash | 77.83 Million | -89.74 Million | 91.4 Million | 49.06 Million | 35.02 Million | -4.96 Million |
| Free Cash Flow | -33.64 Million | -43.36 Million | -150.94 Million | -33.69 Million | -43.43 Million | -35.35 Million |
ADVANC
BH-R
ADVANC-R
300936
BIZOTIC
MPIX